Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Viral clearance, Cox 0% Improvement Relative Risk Viral clearance, logistic re.. 59% Paxlovid for COVID-19  Yang et al.  EARLY TREATMENT Is early treatment with paxlovid beneficial for COVID-19? Retrospective 1,086 patients in China (March - April 2022) c19early.org Yang et al., Infection and Drug Resist.., Mar 2024 Favors paxlovid Favors control

Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China

Yang et al., Infection and Drug Resistance, doi:10.2147/IDR.S443574
Mar 2024  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Retrospective 3,159 high risk COVID-19 patients in China showing no significant difference for viral clearance with multivariable Cox regression, but significantly faster viral clearance with logistic regression. Cox results account for the time to events and can handle censored data, and may be more clinically meaningful because they directly relate to the instantaneous risk of an event occurring. Authors do not discuss the large difference between the Cox and logistic regression results, which may bre related to increased rebound with paxlovid, time-dependent treatment effects, baseline differences, censored data, and unmeasured confounding.
Confounding by contraindication. Hoertel et al. find that over 50% of patients that died had a contraindication for the use of Paxlovid Hoertel. Retrospective studies that do not exclude contraindicated patients may significantly overestimate efficacy.
Black box warning. The FDA notes that "severe, life-threatening, and/or fatal adverse reactions due to drug interactions have been reported in patients treated with paxlovid" FDA.
risk of no viral clearance, 0.5% lower, HR 1.00, p = 0.96, treatment 362, control 724, adjusted per study, inverted to make HR<1 favor treatment, multivariable, Cox proportional hazards.
risk of no viral clearance, 59.0% lower, OR 0.41, p < 0.001, treatment 362, control 724, adjusted per study, inverted to make OR<1 favor treatment, logistic regression, multivariable, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yang et al., 29 Mar 2024, retrospective, China, peer-reviewed, 10 authors, study period March 2022 - April 2022. Contact: drkaijiang@163.com, mingyan1970@126.com.
This PaperPaxlovidAll
Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China
Wei Yang, Yahui Peng, Changsong Wang, Hongliu Cai, Lina Zhang, Jun Xu, Yongjie Wang, Maonan Wang, Mingyan Zhao, Kaijiang Yu
Infection and Drug Resistance, doi:10.2147/idr.s443574
Introduction: The purpose of this study was to compare the viral shedding time in patients infected with the Omicron variant during Paxlovid therapy and conventional therapy and to analyze the effects of Paxlovid on patients infected with COVID-19. Methods: In this study, the demographic and clinical characteristics and laboratory data of 3159 patients infected with the SARS-CoV -2 Omicron variant treated at Jilin Province People's Hospital were collected and analyzed. A total of 362 patients received Paxlovid therapy, and 2797 patients received conventional therapy. After propensity score matching (PSM), 1086 patients were obtained. Results: The difference in platelet (PLT) count between the two groups was statistically significant but within the normal range (P < 0.05). CT value revealed that the nucleic acid test results became negative more quickly in the Paxlovid therapy group. Analysis of the Paxlovid therapy group showed that IgG and IgM levels were increased after Paxlovid therapy administration. Conclusion: The CT value of the Paxlovid therapy group became negative more quickly. This finding suggests that Paxlovid treatment after early diagnosis of the Omicron variant may achieve good therapeutic efficacy.
Conclusions Our data show that the CT value of the Paxlovid therapy group became negative faster than that of the control group, suggesting that the use of the Paxlovid in Omicron variant may achieve excellent therapeutic efficacy after early diagnosis. Moreover, Paxlovid should be used with caution and only in high-risk patients. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure The authors declare that they have no conflicts of interest in this work.
References
Adam, What scientists know about new, fast-spreading coronavirus variants, Nature, doi:10.1038/d41586-021-01390-4
Cegolon, Magnano, Negro, Filon, SARS-CoV-2 reinfections in health-care workers, 1 March 2020-31, Viruses, doi:10.3390/v15071551
Cegolon, Negro, Mastrangelo, Filon, Primary SARS-CoV-2 infections, re-infections and vaccine effectiveness during the Omicron transmission period in healthcare workers of Trieste and Gorizia (Northeast Italy), Viruses, doi:10.3390/v14122688
Cegolon, Pol, Simonetti, Filon, Luzzati, Molnupiravir, nirmatrelvir/ritonavir, or sotrovimab for high-risk COVID-19 patients infected by the Omicron variant: hospitalization, mortality, and time until negative swab test in real life, Pharmaceuticals, doi:10.3390/ph16050721
Chen, Gao, Wang, Wei, Prediction and mitigation of mutation threats to COVID-19 vaccines and antibody therapies, Chem. Sci, doi:10.1039/D1SC01203G
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19, New Engl J Med, doi:10.1056/NEJMoa2118542
Li, Guan, Wu, Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia, New Engl J Med, doi:10.1056/NEJMoa2001316
Li, Li, Li, Zhang, Ma, Clinical characteristics and analysis of factors associated with severe COVID-19 patients in Liaoning, China: a multicenter retrospective study, J Transl Crit Care Med, doi:10.4103/jtccm.jtccm_7_21
Liu, Rocklöv, The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus, J Travel Med, doi:10.1093/jtm/taab124
Long, Carius, Chavez, Clinical update on COVID-19 for the emergency clinician: presentation and evaluation, Am J Emergency Med, doi:10.1016/j.ajem.2022.01.028
Mahase, Covid-19: UK becomes first country to authorise antiviral molnupiravir, BMJ
Mahase, Covid-19: pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports, and Drug Resistance, doi:10.2147/IDR.S443574DovePressInfection
Owen, Allerton, Anderson, An oral SARS-CoV-2 M(pro) inhibitor clinical candidate for the treatment of COVID-19, Science, doi:10.1126/science.abl4784
Viana, Moyo, Amoako, Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa, Nature, doi:10.1038/s41586-022-04411-y
Vito, Moi, Saderi, Vaccination and antiviral treatment reduce the time to negative SARS-CoV-2 Swab: a real-life study, doi:10.3390/v15112180
Zhu, Zhang, Wang, A novel coronavirus from patients with pneumonia in China, 2019, New Engl J Med, doi:10.1056/NEJMoa2001017
{ 'DOI': '10.2147/idr.s443574', 'ISSN': ['1178-6973'], 'URL': 'http://dx.doi.org/10.2147/IDR.S443574', 'author': [ {'affiliation': [], 'family': 'Yang', 'given': 'Wei', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Peng', 'given': 'Yahui', 'sequence': 'additional'}, { 'ORCID': 'http://orcid.org/0000-0002-0079-5259', 'affiliation': [], 'authenticated-orcid': True, 'family': 'Wang', 'given': 'Changsong', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Cai', 'given': 'Hongliu', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Zhang', 'given': 'Lina', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Xu', 'given': 'Jun', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Wang', 'given': 'Yongjie', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Wang', 'given': 'Maonan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Zhao', 'given': 'Mingyan', 'sequence': 'additional'}, {'affiliation': [], 'family': 'Yu', 'given': 'Kaijiang', 'sequence': 'additional'}], 'container-title': 'Infection and Drug Resistance', 'container-title-short': 'IDR', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2024, 3, 29]], 'date-time': '2024-03-29T07:25:09Z', 'timestamp': 1711697109000}, 'deposited': { 'date-parts': [[2024, 3, 29]], 'date-time': '2024-03-29T07:25:14Z', 'timestamp': 1711697114000}, 'indexed': {'date-parts': [[2024, 3, 30]], 'date-time': '2024-03-30T01:17:47Z', 'timestamp': 1711761467663}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2024, 3]]}, 'language': 'en', 'license': [ { 'URL': 'https://creativecommons.org/licenses/by-nc/3.0/', 'content-version': 'unspecified', 'delay-in-days': 0, 'start': { 'date-parts': [[2024, 3, 1]], 'date-time': '2024-03-01T00:00:00Z', 'timestamp': 1709251200000}}], 'link': [ { 'URL': 'https://www.dovepress.com/getfile.php?fileID=97994', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.dovepress.com/getfile.php?fileID=97994', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '301', 'original-title': [], 'page': '1267-1279', 'prefix': '10.2147', 'published': {'date-parts': [[2024, 3]]}, 'published-online': {'date-parts': [[2024, 3]]}, 'publisher': 'Informa UK Limited', 'reference': [ { 'DOI': '10.1056/NEJMoa2001017', 'author': 'Zhu', 'doi-asserted-by': 'publisher', 'first-page': '727', 'journal-title': 'New Engl J Med', 'key': 'ref1', 'volume': '382', 'year': '2020'}, { 'DOI': '10.1056/NEJMoa2001316', 'author': 'Li', 'doi-asserted-by': 'publisher', 'first-page': '1199', 'journal-title': 'New Engl J Med', 'key': 'ref2', 'volume': '382', 'year': '2020'}, { 'DOI': '10.4103/jtccm.jtccm_7_21', 'author': 'Li', 'doi-asserted-by': 'publisher', 'first-page': '90', 'journal-title': 'J Transl Crit Care Med', 'key': 'ref3', 'volume': '2', 'year': '2020'}, { 'key': 'ref4', 'unstructured': 'World Health Organization. WHO Director-General’s opening remarks at the ' 'media briefing on COVID-19; 2020. Available from: ' 'https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-The-media-briefing-on-covid-19---11-march-2020. ' 'Accessed March 11, 2020.'}, { 'key': 'ref5', 'unstructured': 'World Health Organization. Tracking SARS-CoV-2 variants. Available from: ' 'https://www.who.int/en/activities/tracking-SARS-CoV-2-variants. Accessed ' 'February 21, 2022.'}, { 'DOI': '10.1038/s41586-022-04411-y', 'author': 'Viana', 'doi-asserted-by': 'publisher', 'first-page': '679', 'journal-title': 'Nature', 'key': 'ref6', 'volume': '603', 'year': '2022'}, { 'DOI': '10.1038/d41586-021-01390-4', 'author': 'Adam', 'doi-asserted-by': 'publisher', 'first-page': '19', 'journal-title': 'Nature', 'key': 'ref7', 'volume': '594', 'year': '2021'}, { 'key': 'ref8', 'unstructured': 'Centers for Disease Control and Prevention. COVID data tracker: variant ' 'pro-portions; 2022. Available from: ' 'https://covid.cdc.gov/covid-data-tracker/#variant-proportions. Accessed ' 'March 25, 2024.'}, { 'DOI': '10.1039/D1SC01203G', 'author': 'Chen', 'doi-asserted-by': 'publisher', 'first-page': '6929', 'journal-title': 'Chem. Sci.', 'key': 'ref9', 'volume': '12', 'year': '2021'}, { 'DOI': '10.1093/jtm/taab124', 'author': 'Liu', 'doi-asserted-by': 'publisher', 'journal-title': 'J Travel Med', 'key': 'ref10', 'volume': '28', 'year': '2021'}, { 'DOI': '10.1016/j.ajem.2022.01.028', 'author': 'Long', 'doi-asserted-by': 'publisher', 'first-page': '46', 'journal-title': 'Am J Emergency Med', 'key': 'ref11', 'volume': '54', 'year': '2022'}, { 'DOI': '10.3390/v15071551', 'author': 'Cegolon', 'doi-asserted-by': 'publisher', 'first-page': '1551', 'journal-title': 'Viruses', 'key': 'ref12', 'volume': '15', 'year': '2023'}, { 'DOI': '10.3390/v14122688', 'author': 'Cegolon', 'doi-asserted-by': 'publisher', 'first-page': '2688', 'journal-title': 'Viruses', 'key': 'ref13', 'volume': '14', 'year': '2022'}, { 'DOI': '10.1126/science.abl4784', 'author': 'Owen', 'doi-asserted-by': 'publisher', 'first-page': '1586', 'journal-title': 'Science', 'key': 'ref14', 'volume': '374', 'year': '2021'}, { 'DOI': '10.1136/bmj.n2697', 'author': 'Mahase', 'doi-asserted-by': 'crossref', 'first-page': 'n2697', 'journal-title': 'BMJ', 'key': 'ref15', 'volume': '375', 'year': '2021'}, { 'DOI': '10.1136/bmj.n2713', 'author': 'Mahase', 'doi-asserted-by': 'crossref', 'first-page': 'n2713', 'journal-title': 'BMJ', 'key': 'ref16', 'volume': '375', 'year': '2021'}, { 'DOI': '10.3390/ph16050721', 'author': 'Cegolon', 'doi-asserted-by': 'publisher', 'first-page': '721', 'journal-title': 'Pharmaceuticals', 'key': 'ref17', 'volume': '16', 'year': '2023'}, { 'DOI': '10.1056/NEJMoa2118542', 'author': 'Hammond', 'doi-asserted-by': 'publisher', 'first-page': '1397', 'journal-title': 'New Engl J Med', 'key': 'ref18', 'volume': '386', 'year': '2022'}, { 'DOI': '10.3390/v15112180', 'author': 'De Vito', 'doi-asserted-by': 'publisher', 'first-page': '2180', 'journal-title': 'Viruses', 'key': 'ref19', 'volume': '15', 'year': '2023'}], 'reference-count': 19, 'references-count': 19, 'relation': {}, 'resource': { 'primary': { 'URL': 'https://www.dovepress.com/reduced-viral-shedding-time-in-high-risk-covid-19-patients-infected-by-peer-reviewed-fulltext-article-IDR'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Pharmacology (medical)', 'Infectious Diseases', 'Pharmacology'], 'subtitle': [], 'title': 'Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with ' 'Paxlovid: A Real-World Study from China', 'type': 'journal-article', 'volume': 'Volume 17'}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit